TFA
ALXN

Transamerica Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Transamerica Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-232
Closed -$33K – 734
2016
Q1 		$33K Sell
232
-28
-11% -$4.11K ﹤0.01% 426
2015
Q4 		$50K Hold
260
– – ﹤0.01% 408
2015
Q3 		$41K Hold
260
– – ﹤0.01% 408
2015
Q2 		$48K Sell
260
-32
-11% -$5.52K ﹤0.01% 462
2015
Q1 		$51K Buy
292
+32
+12% +$5.79K ﹤0.01% 437
2014
Q4 		$49K Sell
260
-93
-26% -$17.2K ﹤0.01% 364
2014
Q3 		$59K Sell
353
-2,884
-89% -$474K 0.01% 332
2014
Q2 		$507K Buy
3,237
+223
+7% +$35.2K 0.04% 177
2014
Q1 		$459K Sell
3,014
-18
-0.6% -$2.86K 0.05% 170
2013
Q4 		$403K Sell
3,032
-225
-7% -$27K 0.04% 177
2013
Q3 		$379K Buy
+3,257
New +$357K 0.05% 163

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Transamerica Financial Advisors's ALXN Position: Q2 2016 in Review

Transamerica Financial Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 232 shares — an estimated $33K sold.

Transamerica Financial Advisors first reported a position in ALXN in Q3 2013 and held it in 11 quarters. The position peaked at $507K in Q2 2014. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Transamerica Financial Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Transamerica Financial Advisors sold 232 Alexion Pharmaceuticals shares in Q2 2016, an estimated $33K.
  • Transamerica Financial Advisors first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 11 quarters.
  • Transamerica Financial Advisors's Alexion Pharmaceuticals position peaked at $507K in Q2 2014.
  • 533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Transamerica Financial Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.